Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Immunopharmacol Immunotoxicol ; 36(6): 397-403, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25204222

ABSTRACT

OBJECTIVE: To investigated whether CBS3830, a highly selectively inhibitor of p38MAPK, could ameliorate inflammation and intimal hyperplasia in arterialized vein grafts (AVGs). METHODS: Sixty male Sprague-Dawley rats underwent a reversed right jugular vein to common carotid artery interposition graft and were randomly treatment with vehicle (control) or single-dose (3 mg/kg, preoperative) or double-dose (3 mg/kg, preoperative and 4 d postoperative) CBS3830. Twenty rats underwent sham operation. The levels of tumor necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß), and interleukin-6 (IL-6) were determined by ELISA. Vein grafts were analyzed by intimal/medial morphometry, proliferating cell nuclear antigen (PCNA) expression, and p38MAPK phosphorylation. RESULTS: TNF-α, IL-1ß, and IL-6 gradually increased then slowly decreased in AVG rats. However, at 4 d and 7 d, TNF-α levels decreased by 37.5% and 29.5% (p = 0.003, 0.05, respectively) in the single-dose CBS3830 group, and by 37.6% and 32.5%, respectively (both p = 0.003) in the double-dose group compared with those of control. IL-1ß levels significantly reduced at 4 d and 14 d in both dosage groups. IL-6 levels significantly reduced at 7 d in both groups. Intima and medial thickening were significantly reduced in both dosage treated groups at 7, 14, and 28 d (all p = 0.000) compared to the controls. Further study showed CBS3830 inhibited p38MAPK phosphorylation and decreased PCNA expression. CONCLUSIONS: CBS3830 significantly decreases inflammation and intimal hyperplasia in AVGs.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Cell Proliferation/drug effects , Dibenzocycloheptenes/pharmacology , Jugular Veins/transplantation , Tunica Intima/drug effects , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , Animals , Dose-Response Relationship, Drug , Graft Occlusion, Vascular/enzymology , Graft Occlusion, Vascular/immunology , Graft Occlusion, Vascular/pathology , Graft Occlusion, Vascular/prevention & control , Hyperplasia , Immunity, Innate/drug effects , Jugular Veins/enzymology , Jugular Veins/immunology , Jugular Veins/pathology , Male , Proliferating Cell Nuclear Antigen/biosynthesis , Rats, Sprague-Dawley , Tunica Intima/enzymology , Tunica Intima/immunology , Tunica Intima/pathology
2.
Heart Lung Circ ; 22(9): 751-8, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23523564

ABSTRACT

OBJECTIVE: Following bypass surgery vein grafts undergo a remodelling process that can lead to restenosis and ultimately vein graft failure. Signalling through mitogen activated protein kinases (MAPKs) is a key mechanism involved in vein graft failure. Here, we investigated whether CBS3830 (c-a-i-r biosciences GmbH, Tübingen, Germany), a new highly selectively inhibitor of p38 MAPK, has a significant effect on inhibiting intimal, medial and adventitial hyperplasia. METHODS: Sixty specific pathogen free Sprague Dawley male rats were randomly divided into three groups. The control group with a reversed right jugular vein, which is common to carotid artery interposition graft, was compared with sham-operated, and CBS3830 treated animals. Intimal, medial and adventitia morphometric examinations and expression of proliferating cell nuclear antigen (PCNA) were analysed after one, two and four weeks for vein grafts. RESULTS: Intimal, medial and adventitia thickening in CBS3830 group were significantly lower than in the control group at each time point. Moreover, CBS3830 significantly reduced the phosphorylation of p38 MAPK and PCNA expression compared to the control. CONCLUSION: On the basis of the present work, intima, media and adventitia of saphenous vein grafts undergo vascular remodelling after surgery. The new, highly selective p38 MAPK inhibitor, CBS3830, ameliorates intimal, medial, and adventitial remodelling by varying degrees.


Subject(s)
Coronary Artery Bypass , Graft Occlusion, Vascular/prevention & control , Protein Kinase Inhibitors/pharmacology , Saphenous Vein/enzymology , Tunica Intima/enzymology , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , Adventitia/enzymology , Adventitia/pathology , Adventitia/physiopathology , Animals , Gene Expression Regulation/drug effects , Graft Occlusion, Vascular/enzymology , Graft Occlusion, Vascular/pathology , Graft Occlusion, Vascular/physiopathology , Male , Phosphorylation/drug effects , Proliferating Cell Nuclear Antigen/biosynthesis , Rats , Rats, Sprague-Dawley , Saphenous Vein/pathology , Saphenous Vein/physiopathology , Tunica Intima/pathology , Tunica Intima/physiopathology , p38 Mitogen-Activated Protein Kinases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...